Mark Schoenberg - Jun 8, 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/9/2023, 03:26 PM
Previous filing
Feb 2, 2023
Next filing
Sep 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +30K $0.00 30K Jun 8, 2023 Ordinary Shares 30K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2023.